Interindividual variation in response to drug administration is multi-factorial, with genetic factors often contributing significantly. Because of the difficulties in studying drug response in humans, cell-based models are being developed as a means to identify and characterize genetic markers associated with drug response. Particularly with the availability of extensive genotypic (e.g. SNPs and copy number variants) and phenotypic (e.g., gene expression) data for the International HapMap cell lines, investigators have begun to analyze pharmacological endpoints within these lines in efforts to identify clinically important genotype-phenotype relationships. Over the past 5 years, there has been significant growth in the number of PGRN investigators employing cell-based models as a component of their pharmacogenomic research program (Figure 1). Some PGRN groups (PAAR, CREATE, PPII) have utilized the International HapMap and or the Polymorphism Discovery lymphoblastoid cell lines (LCLs) that are commercially available from the Coriell Institute for Medical Research (www.coriell.org/). Other groups have created their own cell lines from individuals with a specific disease such as asthma (PHAT) or hypertension (PEAR), or they have generated cell lines from key individuals in deeply-phenotyped populations such as the Amish (PAPI) or SOPHIE (healthy volunteers) study (PMT). Therefore, providing a resource for the exchange of information generated via the use of cell lines would be highly beneficial to the majority of existing PGRN groups (8 out of 11). This resource will also be of great benefit to PGRN investigators who currently do not use cell-based models, because it will provide them with opportunities to learn about the applications for cell-based research and investigate results of pharmacogenomic studies within this model system.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01GM061393-14
Application #
8522300
Study Section
Special Emphasis Panel (ZRG1-GGG-M)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
14
Fiscal Year
2013
Total Cost
$952,700
Indirect Cost
$341,995
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Maitland, Michael L; Xu, Chun-Fang; Cheng, Yu-Ching et al. (2015) Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res 21:365-72
Karovic, S; Wen, Y; Karrison, T G et al. (2014) Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther 96:27-35
Grassi, Michael A; Rao, Vidhya; Winkler, Kathryn P et al. (2014) Genetic variation is the major determinant of individual differences in leukocyte endothelial adhesion. PLoS One 9:e87883
LaCroix, Bonnie; Gamazon, Eric R; Lenkala, Divya et al. (2014) Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics 15:292
Liu, Wanqing; Ramírez, Jacqueline; Gamazon, Eric R et al. (2014) Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet 23:5558-69
Stark, Amy L; Hause Jr, Ronald J; Gorsic, Lidija K et al. (2014) Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet 10:e1004192
Pinto, N; Gamazon, E R; Antao, N et al. (2014) Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther 95:644-52
Thompson, Patrick; Wheeler, Heather E; Delaney, Shannon M et al. (2014) Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 74:831-8
Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32
Weng, Liming; Ziliak, Dana; Lacroix, Bonnie et al. (2014) Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One 9:e93420

Showing the most recent 10 out of 296 publications